About 1.4m doses of Nuvaxovid to arrive in country this week, after EU approval in December
Germany will offer its population a new protein-based Covid-19 vaccine comparable to conventional flu jabs this week, in the hope of swaying a sizeable minority that remains sceptical of the novel mRNA technology used in the most commonly used vaccines.
About 1.4m doses of the Nuvaxovid vaccine developed by the US biotech company Novavax are to arrive in Germany this week, the country’s health minister, Karl Lauterbach, confirmed last Friday. A further million doses are to arrive the week after, with the German government’s total order for the year 2022 amounting to 34m doses.
